CytomX Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 1.10
Dividend & YieldN/A$ (N/A)
Beta 0.38
Market capitalization 112.34M
Operating cash flow -140.59M
ESG Scores unknown

Company description

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -37.93M -48.12M 30.03M -66.35M
Total Cashflows From Investing Activities 5.93M 79.7M -18.72M 22.49M
Net Borrowings
Total Cash From Financing Activities 139.62M 1.63M 16.89M 110.21M
Change To Operating Activities 19.91M -13.96M -11.12M 11.64M
Issuance Of Stock 139.62M 1.63M 16.89M 110.21M
Net Income -84.6M -102.24M -32.88M -83.61M
Change In Cash 70.03M -59.15M 3.43M 13.67M
Effect Of Exchange Rate
Total Cash From Operating Activities -75.52M -140.48M 5.26M -119.03M
Depreciation 1.88M 2.6M 2.57M 2.71M
Change To Account Receivables 10.04M 84k -785k 8k
Other Cashflows From Financing Activities
Change To Netincome 15.18M 21.15M 17.44M 16.57M
Capital Expenditures -3.79M -3.5M -2.31M -1.61M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 103.87M 131.62M 112.94M 114.19M
Income Before Tax -70.3M -102.67M -46.8M -83.61M
Net Income -84.6M -102.24M -32.88M -83.61M
Selling General Administrative 33.51M 36.77M 36.03M 39.16M
Gross Profit 59.5M 57.49M 100.36M 69.57M
Ebit -77.87M -110.89M -48.6M -83.78M
Operating Income -77.87M -110.89M -48.6M -83.78M
Interest Expense
Income Tax Expense 14.3M -427k -13.91M
Total Revenue 59.5M 57.49M 100.36M 69.57M
Cost Of Revenue
Total Other Income ExpenseNet 7.57M 8.23M 1.81M 172k
Net Income From Continuing Ops -84.6M -102.24M -32.88M -83.61M
Net Income Applicable To Common Shares -84.6M -102.24M -32.88M -83.61M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 326.23M 290.17M 308.86M 250.03M
Total Stockholder Equity 130.88M 51.11M 49.8M 89.38M
Other Current Liabilities 66.05M 51.38M 74.87M 69.26M
Total Assets 457.11M 341.28M 358.66M 339.41M
Common Stock 1k 1k 1k 1k
Other Current Assets
Retained Earnings -314.98M -417.23M -450.12M -533.72M
Treasury Stock -93k 57k -47k -242k
Cash 247.58M 188.43M 191.86M 205.53M
Total Current Liabilities 97.91M 85.59M 100.92M 106.32M
Other Stockholder Equity -93k 57k -47k -242k
Property, Plant, and Equipment 6.93M 32.75M 29.45M 25.32M
Total Current Assets 445.48M 303.33M 324.01M 310.3M
Net Tangible Assets 128.48M 48.85M 47.69M 87.41M
Net Receivables 97k 13k 798k 790k
Accounts Payable 5.13M 4.16M 3M 2.82M


Insider Transactions

Here are the insider transactions of stock shares related to CytomX Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
ROWLAND LLOYD ASale at price 1.42 per share.D2022-07-20General Counsel5.6k
HANNAH ALISON L.Sale at price 1.42 per share.D2022-07-20Officer5.6k
MCCARTHY SEAN A.Sale at price 1.42 per share.D2022-07-20Chief Executive Officer14.91k
PETERSON AMY CSale at price 1.42 per share.D2022-07-20Officer7.46k
CAMPOY CARLOSSale at price 1.42 per share.D2022-07-20Chief Financial Officer3.95k
LANDAU JEFFREY BSale at price 1.42 per share.D2022-07-20Officer4.21k
ROWLAND LLOYD AStock Award(Grant) at price 0.00 per share.D2022-07-19General Counsel15k
HANNAH ALISON L.Stock Award(Grant) at price 0.00 per share.D2022-07-19Officer15k
MCCARTHY SEAN A.Stock Award(Grant) at price 0.00 per share.D2022-07-19Chief Executive Officer40k
PETERSON AMY CStock Award(Grant) at price 0.00 per share.D2022-07-19Officer20k
CAMPOY CARLOSStock Award(Grant) at price 0.00 per share.D2022-07-19Chief Financial Officer15k
LANDAU JEFFREY BStock Award(Grant) at price 0.00 per share.D2022-07-19Officer11.25k
MCCARTHY SEAN A.Conversion of Exercise of derivative security at price 0.94 per share.D2022-05-09Chief Executive Officer90.93k
ROWLAND LLOYD AStock Award(Grant) at price 0.00 per share.D2022-02-02General Counsel22.5k
HANNAH ALISON L.Stock Award(Grant) at price 0.00 per share.D2022-02-02Officer22.5k
MCCARTHY SEAN A.Stock Award(Grant) at price 0.00 per share.D2022-02-02Chief Executive Officer75k
PETERSON AMY CStock Award(Grant) at price 0.00 per share.D2022-02-02Officer40k
CAMPOY CARLOSStock Award(Grant) at price 0.00 per share.D2022-02-02Chief Financial Officer22.5k
MCCARTHY SEAN A.Conversion of Exercise of derivative security at price 1.13 per share.D2021-08-11Chief Executive Officer92.11k
MCCARTHY SEAN A.Sale at price 7.04 per share.I2021-06-16Chief Executive Officer100k
MCCARTHY SEAN A.Conversion of Exercise of derivative security at price 0.94 - 1.13 per share.D2021-06-14Chief Executive Officer40
PETERSON AMY CStock Award(Grant) at price 6.09 per share.D2021-05-31Officer3.32k
CAMPOY CARLOSStock Award(Grant) at price 6.09 per share.D2021-05-31Chief Financial Officer3.32k
MCCARTHY SEAN A.Sale at price 7.49 per share.D2021-03-31Chief Executive Officer100k
MCCARTHY SEAN A.Conversion of Exercise of derivative security at price 1.13 per share.D2021-03-31Chief Executive Officer100k
MCCARTHY SEAN A.Conversion of Exercise of derivative security at price 1.13 per share.D2020-12-23Chief Executive Officer100k
MCCARTHY SEAN A.Stock Award(Grant) at price 6.39 per share.D2020-11-30Chief Executive Officer930
PETERSON AMY CStock Award(Grant) at price 6.39 per share.D2020-11-30Officer3.1k
CAMPOY CARLOSStock Award(Grant) at price 6.39 per share.D2020-11-30Chief Financial Officer3.1k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to CytomX Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on CytomX Therapeutics Inc

Here is the result of two systematic investment strategies applied to CytomX Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on CytomX Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to CytomX Therapeutics Inc:

CytomX Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -31.86% on the backtest period.

Performance at glance

Performance

-31.86 %

Latent gain

-558.56 $

Invested capital

1753.16 $

Annualized return

-7.77 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on CytomX Therapeutics Inc

This is the result of two momentum investment strategies applied to CytomX Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on CytomX Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on CytomX Therapeutics Inc:

CytomX Therapeutics Inc momentum entries
  • The first momentum investment strategy would give -20.17% of return on CytomX Therapeutics Inc. That represents -1015.79$ of latent gain with 5035.19$ of employed capital.
  • The second momentum investment strategy would give -20.08% of return on CytomX Therapeutics Inc. That represents -601.79$ of latent gain with 2997.59$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-20.17 %

Latent gain

-1015.79 $

Invested capital

5035.19 $

Annualized return

0.89 %
Performance at glance (2Q Momentum)

Performance

-20.08 %

Latent gain

-601.79 $

Invested capital

2997.59 $

Annualized return

-5.55 %

Momentum equity curve on CytomX Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to CytomX Therapeutics Inc:

CytomX Therapeutics Inc momentum equity

Note: the dividends potentially given by CytomX Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on CytomX Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on CytomX Therapeutics Inc since the beginning:

CytomX Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on CytomX Therapeutics Inc

Buy the dip entry openings on CytomX Therapeutics Inc

CytomX Therapeutics Inc

The performance achieved by the robo-advisor on CytomX Therapeutics Inc is 1.86%. That represents 13.96$ of latent gain with 751.64$ of employed capital. The following chart shows CytomX Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of CytomX Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

1.86 %

Latent gain

13.96 $

Invested capital

751.64 $

Annualized return

0.89 %

Equity curve of the strategy applied to CytomX Therapeutics Inc

The following chart shows the result of the investment strategy applied to CytomX Therapeutics Inc:

CytomX Therapeutics Inc

Note: the dividends potentially given by CytomX Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on CytomX Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on CytomX Therapeutics Inc:

CytomX Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on CytomX Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to CytomX Therapeutics Inc.

Equity curve comparison on CytomX Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

CytomX Therapeutics Inc investment strategy comparison

Employed capital comparison on CytomX Therapeutics Inc

CytomX Therapeutics Inc investment comparison

Performance comparison on CytomX Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -31.86% -558.56$ 1753.16$ -7.77%
Momentum 1 quarter -20.17% -1015.79$ 5035.19$ -5.23%
Momentum 2 quarters -20.08% -601.79$ 2997.59$ -5.55%
Non-directional 1.86% 13.96$ 751.64$ 0.89%
Annualized return comparison

Automatic investment

-7.77 %

Momentum 1Q

-5.55 %

Momentum 2Q

-5.55 %

Non-directional

0.89 %

Correlated stocks

Here are the most positively and negatively correlated stocks with CytomX Therapeutics Inc:

Positive correlations

Most correlated stocks this year

  • CytomX Therapeutics Inc

  • Most correlated stocks last 3 months

  • CytomX Therapeutics Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • MACKENZIE CDN LARGE CAP EQUITY INDEX ETF

  • Note: The algorithm computes the probability of correlation between CytomX Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of CytomX Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name CytomX Therapeutics Inc
    Country United States
    City South San Francisco
    Address 151 Oyster Point Boulevard
    Phone 650 515 3185
    Website www.cytomx.com
    FullTime employees 174
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker CTMX
    Market www.nasdaq.com

    CytomX Therapeutics Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown